Indications
Arformoterol Tartrate is indicated for long-term use, twice a day (morning and evening), as maintenance treatment of broncho-constriction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Aroneb is indicated for the same use. Important limitations of use: Arformoterol Tartrate nebuliser solution is not indicated to treat acute deteriorations of COPD. People with asthma who take long-acting beta 2 adrenergic agonist (LABA) medicines, such as Arformoterol Tartrate, have an increased risk of death from asthma problems.
⚠️ Always consult a registered physician before taking any medicine.
Pregnancy & Breastfeeding
Arformoterol Tartrate falls under Pregnancy Category C. The nebuliser solution should be used during pregnancy only if the possible benefit justifies the possible risk to the fetus. Doctors also don't know whether arformoterol passes into human milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.